What is the clinical evidence from this study?

Study design: Review. Population: Breast cancer. Intervention: Systemic breast cancer treatments. Primary outcome: Cardiotoxicity.

What does this research mean for the field?

Systemic breast cancer treatments, including anthracyclines and anti-HER2 agents, cause distinct forms of cardiotoxicity that can be identified and managed using cardiac biomarkers and functional tests. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 1, 2014The BreastOpen Access

Cardiotoxicity of systemic agents used in breast cancer

View Full Paper

Ask AI

Bookmark

Key result

Systemic breast cancer treatments drive cardiotoxicity that may be managed using next-generation cardiac biomarkers.

Why the study?

What are the cardiotoxic profiles of systemic agents used in breast cancer and how can they be monitored?

Population

Patients receiving systemic therapies for breast cancer

Design

Review

Authors

FAFelipe AdesBristol-Myers Squibb (United States)DZDimitrios ZardavasBristol-Myers Squibb (United States)APAna Catarina PintoUniversidade do Porto

Discussion

Member takes

Implication

May inform cardiotoxicity awareness in breast cancer care; leaves open prospective validation of emerging biomarkers.

Structured PICO

What are the cardiotoxic profiles of systemic agents used in breast cancer and how can they be monitored?

Population

Patients receiving systemic therapies for breast cancer

Exposure

Systemic breast cancer treatments including anthracyclines, anti-HER2 agents, endocrine therapy, antiangiogenics, and mTOR inhibitors

Outcome

Cardiotoxicity (including permanent cardiac damage, reversible cardiac dysfunction, and lipid metabolism disturbances)safety

This review summarizes the cardiotoxic profiles of various breast cancer therapies and highlights the role of biomarkers and functional tests in optimizing treatment and preventing cardiotoxicity.

Limitations

Longer follow-up is needed to fully understand the toxicity profiles of new drugs.

Cite This Study

Ades et al. (2014) conducted a review in Breast cancer. Systemic breast cancer treatments was evaluated on Cardiotoxicity. Systemic breast cancer treatments, including anthracyclines and anti-HER2 agents, can cause cardiotoxicity, which may be managed using current and next-generation cardiac biomarkers.

synapsesocial.com/papers/6aa5895bbc2c7db7488e4218 https://doi.org/10.1016/j.breast.2014.04.002

Topics

Heart failure HFrEF treatment Women and heart disease Cardio-oncology

View Full Paper

Ask AI

Bookmark

Cardiotoxicity of systemic agents used in breast cancer

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Cardiotoxicity of systemic agents used in breast cancer

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider